276
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A Case of Idiopathic Retinitis Vasculitis Aneurysms and Neuroretinitis (IRVAN) Treated with Adalimumab

, MS, , MD, , DNB, , MD & , DNB
Pages 627-630 | Received 20 Sep 2021, Accepted 23 Nov 2021, Published online: 22 Mar 2022
 

ABSTRACT

Purpose

To report a case of IRVAN in a 13-year-old girl responding well to Adalimumab and Azathioprine.

Results

A 13-year-old girl presented to us with central scotoma for a duration of 10 months. She was treated earlier with oral steroids with poor response. Fundus examination revealed features of IRVAN. She was treated with intravitreal dexamethasone implant in both eyes with oral Mycophenolate Mofetil (MMF) with transient response to it. So she was switched over to subcutaneous Adalimumab 40 mg once in 2 weeks and oral Azathioprine 50 mg BD. The disease activity was well controlled with the current regime.

Conclusion

Though various treatment modalities have been described in literature for the treatment of IRVAN. This is the first case of IRVAN to be treated with Adalimumab along with Azathioprine to be reported.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Summary

Idiopathic retinal vasculitis, Aneurysms and neuroretinitis (IRVAN) is a rare clinical entity of unknown etiology with no definitive guidelines for its medical management. We report a case of IRVAN with good response to fortnightly subcutaneous Adalimumab and daily oral Azathioprine with no systemic side effects on follow-up.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.